Oligomer-targeting with a conformational antibody fragment promotes toxicity in Aβ-expressing flies

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Wacker, Jessica ^a,h   Rönicke, Raik ^b   Westermann, Martin ^c   Wulff, Melanie ^a,d   Reymann, Klaus G ^b   Dobson, Christopher M ^e   Horn, Uwe ^f   Crowther, Damian C ^e,g   Luheshi, Leila M ^e   Fändrich, Marcus ^a,d  

^a MAX PLANCK RESEARCH UNIT FOR ENZYMOLOGY OF PROTEIN FOLDING   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f HANS KNÖLL INSTITUTE   (Germany)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h MVZ Labor Dessau GmbH   (Germany)

Author keywords

Conformational disease; Misfolding; Neurodegeneration; Prion; Protein aggregation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); ANTIBODY; DROSOPHILA PROTEIN; PEPTIDE FRAGMENT; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DROSOPHILA MELANOGASTER; DRUG EFFECTS; EYE; GENETICS; HIPPOCAMPUS; HUMAN; IMMUNOLOGY; LONG TERM POTENTIATION; METABOLISM; MOUSE; NEUROBLASTOMA; NEUROTOXICITY SYNDROMES; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN CONFORMATION; PROTEINOSIS; TRANSGENIC ANIMAL; TUMOR CELL LINE; ULTRASTRUCTURE;

AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; EYE; HIPPOCAMPUS; HUMANS; LONG-TERM POTENTIATION; MICE; MICE, INBRED C57BL; NEUROBLASTOMA; NEUROTOXICITY SYNDROMES; PEPTIDE FRAGMENTS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 84908021295     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-2-43     Document Type: Article

References (56)

1. Eisenberg D, Jucker M: The amyloid state of proteins in human diseases. Cell 2012, 148: 1188-1203. 10.1016/j.cell.2012.02.022
2. Bellotti V, Mangione P, Merlini G: Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349: 583-596. 10.1056/NEJMra023144
3. Chiti F, Dobson CM: Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006, 75: 333-366. 10.1146/annurev.biochem.75.101304.123901
4. Eichner T, Radford SE: A diversity of assembly mechanisms of a generic amyloid fold. Mol Cell 2011, 43: 8-18. 10.1016/j.molcel.2011.05.012
5. Dodel RC, Hampel H, Du YS: Immunotherapy for Alzheimer's disease. Lancet Neurol 2003, 2: 215-220. 10.1016/S1474-4422(03)00349-1
6. Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid bold beta-peptide. Nat Rev Mol Cell Biol 2007, 8: 101-112. 10.1038/nrm2101
7. Ittner LM, Götz J: Amyloid-β and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011, 12: 65-72.
8. Walsh DM, Teplow DB: Alzheimer's disease and the amyloid β protein. Prog Mol Biol Tranls 2012, 107: 101-124.
9. Morgado I, Fändrich M: Review: assembly of Alzheimer's Aβ peptide into nanostructured amyloid fibrils. Curr Opin Colloid In 2011, 16: 508-514. 10.1016/j.cocis.2011.06.016
10. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Näslund J, Lannfelt L: The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001, 4: 887-893. 10.1038/nn0901-887
11. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Birgit Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S: Glutaminyl cyclase inhibition attenuates pyroglutamate Abold beta and Alzheimer's disease-like pathology. Nat Med 2008, 14: 1106-1111. 10.1038/nm.1872
12. Lashuel HA, Lansbury PT Jr: Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 2006, 39: 167-201. 10.1017/S0033583506004422
13. Cherny I, Gazit E: Amyloids: not only pathological agents but also ordered nanomaterials. Angew Chem Int Edit 2008, 47: 4062-4069. 10.1002/anie.200703133
14. Fändrich M: Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. J Mol Biol 2012, 421: 427-440. 10.1016/j.jmb.2012.01.006
15. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-β protein assembly in the brain impairs memory. Nature 2005, 440: 352-357.
16. Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M: Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 2008, 27: 224-233. 10.1038/sj.emboj.7601953
17. Glabe CG: Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem Sci 2004, 29: 542-547. 10.1016/j.tibs.2004.08.009
18. O'Nuallain B, Ronald Wetzel R: Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A 2002, 99: 1485-1490. 10.1073/pnas.022662599
19. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM: Structure-based design of conformation- and sequence-specific antibodies against amyloid β. Proc Natl Acad Sci U S A 2012, 109: 84-89. 10.1073/pnas.1111232108
20. Nerelius C, Sandegren A, Sargsyan H, Raunak R, Leijonmarck H, Chatterjee U, Fisahn A, Imarisio S, Lomas DA, Crowther DC, Strömberg R, Johansson J: Alpha-helix targeting reduces amyloid-beta peptide toxicity. Proc Natl Acad Sci U S A 2009, 106: 9191-9196. 10.1073/pnas.0810364106
21. Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A: Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS ONE 2009, 4(5):e5727. doi:10.1371/journal.pone.0005727 10.1371/journal.pone.0005727
22. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, Gubb DC, Lomas DA: Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 2005, 132: 123-135. 10.1016/j.neuroscience.2004.12.025
23. Luheshi LM, Tartaglia GG, Brorsson AC, Pawar AP, Watson IE, Chiti F, Vendruscolo M, Lomas DA, Dobson CM, Crowther DC: Systematic in vivo analysis of the intrinsic determinants of amyloid Beta pathogenicity. PLoS Biol 2007, 5(11):e290. doi:10.1371/journal.pbio.0050290 10.1371/journal.pbio.0050290
24. Rival T, Page RM, Chandraratna DS, Sendall TJ, Ryder E, Liu B, Lewis H, Rosahl T, Hider R, Camargo LM, Shearman MS, Crowther DC, Lomas DA: Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease. Eur J Neurosci 2009, 29: 1335-1347. 10.1111/j.1460-9568.2009.06701.x
25. Liu B, Moloney A, Meehan S, Morris K, Thomas SE, Serpell LC, Hider R, Marciniak SJ, Lomas DA, Crowther DC: Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem 2011, 286: 4248-4256. 10.1074/jbc. M110.158980
26. Sofola O, Kerr F, RogersI KK, Augustin H, Gandy C, Allen MJ, Hardy J, Lovestone S, Partridge L: Inhibition of GSK-3 ameliorates Aβ pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet 2010, 6(9):e1001087. doi:10.1371/journal.pgen.1001087 10.1371/journal.pgen.1001087
27. Auluck PK, Caraveo G, Lindquist S: α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol 2010, 26: 211-233. 10.1146/annurev.cellbio.042308.113313
28. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB: Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001, 293: 711-714. 10.1126/science.1062382
29. Morgado I, Wieligmann K, Bereza M, Rönicke R, Meinhardt K, Annamalai K, Baumann M, Wacker J, Hortschansky P, Malešević M, Parthier C, Mawrin C, Schiene-Fischer C, Reymann KG, Stubbs MT, Balbach J, Görlach M, Horn U, Fändrich M: Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment. Proc Natl Acad Sci U S A 2012, 109: 12503-12508. 10.1073/pnas.1206433109
30. Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C, Meinhardt J, Wieligmann K, Gellermann GP, Brodhun M, Götz J, Halbhuber KJ, Röcken C, Horn U, Fändrich M: Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc Natl Acad Sci U S A 2007, 104: 19232-19237. 10.1073/pnas.0703793104
31. Haupt C, Morgado I, Kumar ST, Parthier C, Bereza M, Hortschansky P, Stubbs MT, Horn U, Fändrich M: Amyloid fibril recognition with the conformational B10 antibody fragment depends on electrostatic interactions. J Mol Biol 2011, 405: 341-348. 10.1016/j.jmb.2010.10.059
32. Haupt C, Bereza M, Kumar ST, Kieninger B, Morgado I, Hortschansky P, Fritz G, Röcken C, Horn U, Fändrich M: Pattern recognition with a fibril-specific antibody fragment reveals the surface variability of natural amyloid fibrils. J Mol Biol 2011, 408: 529-540. 10.1016/j.jmb.2011.02.032
33. Upadhaya AR, Lungrin I, Yamaguchi H, Fändrich M, Thal DR: High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain. J Cell Mol Med 2012, 16: 287-295. 10.1111/j.1582-4934.2011.01306.x
34. Kieninger B, Gioeva Z, Krüger S, Westermark GT, Friedrich RP, Fändrich M, Röcken C: PTAA and B10: new approaches to amyloid detection in tissue-evaluation of amyloid detection in tissue with a conjugated polyelectrolyte and a fibril-specific antibody fragment. Amyloid 2011, 18: 47-52. 10.3109/13506129.2011.560623
35. Scheidt HA, Morgado I, Rothemund S, Huster D, Fändrich M: Solid-state NMR spectroscopic investigation of Aβ protofibrils: implication of a β-sheet remodeling upon maturation into terminal amyloid fibrils. Angew Chem Int Ed Engl 2011, 50: 2837-2840. 10.1002/anie.201007265
36. Hortschansky P, Schroeckh V, Christopeit T, Zandomeneghi G, Fändrich M: The aggregation kinetics of Alzheimer's β-amyloid peptide is controlled by stochastic nucleation. Prot Sci 2005, 14: 1753-1759. 10.1110/ps.041266605
37. Haupt C, Leppert J, Rönicke R, Meinhardt J, Yadav JK, Ramachandran R, Ohlenschläger O, Reymann KG, Görlach M, Fändrich M: Structural basis of β-amyloid-dependent synaptic dysfunctions. Angew Chem Int Ed 2012, 7: 1576-1577.
38. Bischof K: An optimized transgenesis system for Drosophila using germ-line-specific φC31 integrases. Proc Natl Acad Sci U S A 2007, 104: 3312-3317. 10.1073/pnas.0611511104
39. Green C, Levashina E, McKimmie C, Dafforn T, Reichhart JM, Gubb D: The necrotic gene in Drosophila corresponds to one of a cluster of three serpin transcripts mapping at 43A1.2. Genetics 2000, 156: 1117-1127.
40. Brand AH, Perrimon N: Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 1993, 118: 401-415.
41. Speretta E, Jahn TR, Tartaglia GG, Favrin G, Barros TP, Imarisio S, Lomas DA, Luheshi LM, Crowther DC, Dobson CM: Expression in drosophila of tandem amyloid beta peptides provides insights into links between aggregation and neurotoxicity. J Biol Chem 2012, 287: 20748-20754. 10.1074/jbc. M112.350124
42. Ashburner M, Golic KG, Hawley RS: Drosophila: a laboratory handbook. 2nd edition. Cold Spring Harbor, New York: Cold Spring Harbor Laborators Press; 2005. XXVIII 1408pp
43. Christopeit T, Hortschansky P, Schroeckh V, Gührs K, Zandomeneghi G, Fändrich M: Mutagenic analysis of the nucleation propensity of oxidized Alzheimer's β-amyloid peptide. Protein Sci 2005, 14: 2125-2131. 10.1110/ps.051470405
44. Gill SC, von Hippel PH: Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 1989, 182: 319-326. 10.1016/0003-2697(89)90602-7
45. Rönicke R, Mikhaylova M, Rönicke S, Meinhardt J, Schröder UH, Fändrich M, Reiser G, Kreutz MR, Reymann KG: Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol Aging 2011, 32: 2219-2228. 10.1016/j.neurobiolaging.2010.01.011
46. Rönicke R, Klemm A, Meinhardt J, Schröder UH, Fändrich M, Reymann KG: Abeta mediated diminution of MTT reduction-an artefact of single cell culture? PLoS ONE 2008, 3(9):e3236. doi:10.1371/journal.pone.0003236 10.1371/journal.pone.0003236
47. Bolognesi B, Kumita JR, Barros TP, Esbjorner EK, Luheshi LM, Crowther DC, Wilson MR, Dobson CM, Favrin G, Yerbury JJ: ANS binding reveals common features of cytotoxic amyloid species. ACS Chem Biol 2010, 5: 735-740. 10.1021/cb1001203
48. Krishnan R, Goodman JL, Mukhopadhyay S, Pacheco CD, Lemke EA, Deniz AA, Lindquist S: Conserved features of intermediates in amyloid assembly determine their benign or toxic states. Proc Natl Acad Sci U S A 2012, 109: 11172-11177. 10.1073/pnas.1209527109
49. Luheshi LM, Hoyer W, Pereira de Barros T, van Dijk HI, Brorsson AC, Macao B, Persson C, Crowther DC, Lomas DA, Stahl S, Dobson CM, Härd T: Sequestration of the Abeta peptide prevents toxicity and promotes degradation in vivo. PLoS Biol 2010, 8(3):e1000334. doi:10.1371/journal.pbio.1000334 10.1371/journal.pbio.1000334
50. Wang XP, Zhang JH, Wang YJ, Feng Y, Zhang X, Sun XX, Li JL, Du XT, Lambert MP, Yang SG, Zhao M, Klein WL, Liu RT: Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBS Lett 2009, 583: 579-584. 10.1016/j.febslet.2008.12.064
51. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL: Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies. J Neurochem 2001, 79: 595-605.
52. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300: 486-489. 10.1126/science.1079469
53. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM: Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006, 281: 4292-4299. 10.1074/jbc. M511018200
54. Goñi F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, Liang FX, Kascsak R, Kascsak R, Mehta P, Wisniewski T: Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5(10):e13391. doi:10.1371/journal.pone.0013391 10.1371/journal.pone.0013391
55. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Müller R, Nimmrich V, Nolte MW, Perez-Cruz C, van der Auwera I, van Leuven F, van Gaalen M, Bespalov AY, Schoemaker H, Sullivan JP, Ebert U: Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci 2010, 30: 10369-10379. 10.1523/JNEUROSCI.5721-09.2010
56. Shughrue PJ, Acton PJ, Breese RS, Zhao WQ, Chen-Dodson E, Hepler RW, Wolfe AL, Matthews M, Heidecker GJ, Joyce JG, Villarreal SA, Kinney GG: Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiol Aging 2010, 31: 189-202. 10.1016/j.neurobiolaging.2008.04.003